The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase II trial of the PARP inhibitor, niraparib, in BAP1 and other DNA damage response (DDR) pathway deficient neoplasms (NCT03207347).
 
azka ali
No Relationships to Disclose
 
David L. DeRemer
Honoraria - Bristol-Myers Squibb (I); Pfizer (I)
Consulting or Advisory Role - Amgen
Speakers' Bureau - Bristol-Myers Squibb (I); Pfizer (I)
 
Ji-Hyun Lee
No Relationships to Disclose
 
Hiral D. Parekh
No Relationships to Disclose
 
Stephen Staal
No Relationships to Disclose
 
Merry Jennifer Markham
Research Funding - Aduro Biotech (Inst); Lilly (Inst); Novartis (Inst); Tesaro (Inst); VBL Therapeutics (Inst)
 
Karen Colleen Daily
Consulting or Advisory Role - Pfizer
 
Bruce K. Stechmiller
No Relationships to Disclose
 
Dennie V. Jones
Consulting or Advisory Role - Bayer
 
Julia Lee Close
No Relationships to Disclose
 
Martina Cathryn Murphy
Consulting or Advisory Role - Pfizer
 
Frederic J. Kaye
No Relationships to Disclose
 
Carmen Joseph Allegra
No Relationships to Disclose
 
Robert A. Hromas
No Relationships to Disclose
 
Thomas J. George
Research Funding - AstraZeneca/MedImmune (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Incyte (Inst); Ipsen (Inst); Lilly (Inst); Merck (Inst); Newlink Genetics (Inst); Pharmacyclics (Inst); Seagen (Inst); Tesaro (Inst)